Daiichi Sankyo Company, Limited

Daiichi Pharmaceutical Co., Ltd.

Masatoshi Nagamochi

Rie Miyauchi

Toshiharu Yoshino

Hideyuki Kanno

Kenji Yoshikawa

Satoshi Komoriya

Noriyasu Haginoya

Tsutomu Nagata

Makoto Ono

Makoto Takemura

Hisashi Takahashi

Toshiharu Ohta

Hiroyuki Naito

Isao Hayakawa

Kouichi Uoto

Shin Iimura

Sunanda Ghosh Dastidar

Ashwani Kumar Verma

Junichi Kuroyanagi

Masayuki Ishizaki

Akiyoshi Mochizuki

Syozo Kobayashi

Punit Kumar Srivastava

Yumi Nakamoto

Kumaragurubaran Nagaswamy

Takeshi Murata

Yogesh Balasaheb Khairnar

Pramod Raosaheb Markad

Sonali Nanasaheb Pansare

Pradip Balu Wagh

Rijwan Jaffer Momin

Aniruddha Mondal

Balkrishna Ramchandra Kale

Soma Ghosh

Lalima Sharma

Kenichi Yoshida

Kiyoshi Nakayama

Takahiro Kitamura

Hiroaki Inagaki

Takashi Odagiri

Toshifumi Tsuda

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R, Rand Rare as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

Heterocyclic compounds as protein kinase inhibitors

A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure. 

Fused substituted aminopyrrolidine derivative

A quinolone antibacterial compound, or a salt or hydrate of the compound, for the treatment of infectious diseases, which exhibit potent antibacterial activity and higher selective toxicity against Gram-positive and Gram-negative bacteria, which do not cause side effects (e.g., convulsion), which exhibit higher safety, and which has a structure of formula (I): 

Substituted pyrrolidine derivative

The invention relates a compound represented by the formula (1):Q-Q-C(&#x2550;O)&#x2014;N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)wherein Rand Rrepresent H or the like; Qrepresents an aromatic ring, heterocyclic ring or the like; Qrepresents a single bond, aromatic ring, heterocyclic ring or the like; Qrepresents a group or the like, Qrepresents an aromatic ring, heterocyclic ring or the like; and Trepresents &#x2014;CO&#x2014; or &#x2014;SO&#x2014;, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Ethylenediamine derivatives

A compound represented by formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)[wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qrepresents the following group: (wherein Qis an alkylene group having 1 to 8 carbon atoms, or the like); and Tand Tare carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qis a group in which Qis an alkylene group having 1 to 8 carbon atoms, or the like; and Tand Tare carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

The invention relates a compound represented by the formula (1):Q-Q-C(&#x2550;O)&#x2014;N(R)-Q-N(R)-T-Q&#x2003;&#x2003;()wherein Rand Rrepresent H or the like; Qrepresents an aromatic ring, heterocyclic ring or the like; Qrepresents a single bond, aromatic ring, heterocyclic ring or the like; Qrepresents a groupor the like, Qrepresents an aromatic ring, heterocyclic ring or the like; and Trepresents &#x2014;CO&#x2014; or &#x2014;SO&#x2014;, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Growing community of inventors

Tokyo, Japan

Masatoshi Nagamochi